Welcome to the Pfizer Co-Pay Portal

ADCETRIS^® (brentuximab vedotin)
Terms and Conditions:
By using the Pfizer Oncology Together™ Co-Pay Savings Program for Injectables for ADCETRIS, you acknowledge that you currently meet the eligibility criteria and will comply with the terms and conditions described below:

• Eligible patients with commercial prescription drug insurance coverage for ADCETRIS may pay as little as $0 per administered dose. Patient out-of-pocket expense will vary. The value of this offer is limited to annual benefit of $15,000. Once a patient reaches the annual maximum benefit patient is responsible for paying the remaining monthly out-of-pocket costs.
• Patients are not eligible for this offer if they are enrolled in a state or federally funded insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veteran Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico (formerly known as “La Reforma de Salud”).
• Patient must have private insurance. Offer is not valid for cash paying patients.
• This offer is not valid when the entire cost of your prescription drug is eligible to be reimbursed by your private insurance plan or other private health or pharmacy benefit programs.
• You must deduct the value of this offer from any reimbursement request submitted to your private insurance plan, either directly by you or on your behalf.
• You are responsible for reporting use of the Pfizer Oncology Together Co-Pay Savings Program for Injectables for ADCETRIS to any private insurer, health plan, or other third party who pays for or reimburses any part of the prescription filled using the co-pay card, as may be required. You should not use the co-pay card if your insurer or health plan prohibits use of manufacturer co-pay cards.
• You must be 2 years of age or older to redeem the co-pay card.
• The Pfizer Oncology Together Co-Pay Savings Program for Injectables for ADCETRIS is not valid where prohibited by law.
• The benefit under the Pfizer Oncology Together Co-Pay Savings Program for Injectables for ADCETRIS is offered to, and intended for the sole benefit of, eligible patients and may not be transferred to or utilized for the benefit of third parties, including, without limitation, third party payers, pharmacy benefit managers, or the agents of either.
• Third party payers, pharmacy benefit managers, or the agents of either, are prohibited from assisting patients with enrolling in the Pfizer Oncology Together Co-Pay Savings Program for Injectables for ADCETRIS.
• The Pfizer Oncology Together Co-Pay Savings Program for Injectables for ADCETRIS cannot be combined with any other external savings, free trial or similar offer for the specified prescription (including any program offered by a third party payer or pharmacy benefit manager, or an agent of either, that adjusts patient cost-sharing obligations, through arrangements that may be referred to as “accumulator adjustment” or “co-pay maximizer” programs)
• Some health insurers or pharmacy benefit managers (or their agents) may have established accumulator adjustment or co-pay maximizer programs based on the availability of support under the Pfizer Oncology Together Co-Pay Savings Program for Injectables for ADCETRIS and/or exclude the financial assistance provided under the offer co-pay card program from counting towards patient deductibles or out-of-pocket cost limitations.
• Patients subject to an accumulator adjustment or co-pay maximizer program are not eligible for this offer. Since you may be unaware whether you are subject to an accumulator adjustment or co-pay maximizer program when you enroll in this offer, Pfizer may monitor program utilization data and reserves the right to discontinue, reduce, or otherwise modify this offer at any time without notice.
• Co-pay card will be accepted only at participating pharmacies.
• If your pharmacy does not participate, you may be able to submit a request for a rebate in connection with this offer.
• The Pfizer Oncology Together Co-Pay Savings Program for Injectables for ADCETRIS is not health insurance.
• Offer good only in the U.S. and Puerto Rico.
• The Pfizer Oncology Together Co-Pay Savings Program for Injectables for ADCETRIS is limited to 1 per person during this offering period and is not transferable.
• No other purchase is necessary.
• Data related to your redemption of the Pfizer Oncology Together Co-Pay Savings Program for Injectables for ADCETRIS may be collected, analyzed, and shared with Pfizer, for market research and other purposes related to assessing Pfizer’s programs. Data shared with Pfizer will be aggregated and de-identified; it will be combined with data related to other co-pay card redemptions and will not identify you.
• Pfizer reserves the right to rescind, revoke or amend this offer without notice.
• Offer expires 12/31/2026.
• For questions regarding the offer, please call 1-877-744-5675, visit https://www.pfizeroncologytogether.com/ or write Pfizer Oncology Together Co-Pay Savings Program for Injectables, 2730 S. Edmonds Lane, Suite 300, Lewisville, TX 75067.

ELELYSO^® (taliglucerase alfa)
Terms and Conditions:
By using this ELELYSO Co-pay Program, you acknowledge that you currently meet the eligibility criteria and will comply with the terms and conditions described below:

• Eligible patients with commercial prescription drug insurance coverage for ELELYSO may pay as little as $0 per administered dose. Patient out-of-pocket expense will vary. The value of this offer is limited to annual benefit of $15,000. Once a patient reaches the annual maximum benefit patient is responsible for paying the remaining monthly out-of-pocket costs.
• Patients are not eligible for this offer if they are enrolled in a state or federally funded insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veteran Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico (formerly known as “La Reforma de Salud”).
• Patient must have private insurance. Offer is not valid for cash paying patients.
• This offer is not valid when the entire cost of your prescription drug is eligible to be reimbursed by your private insurance plan or other private health or pharmacy benefit programs.
• You must deduct the value of this offer from any reimbursement request submitted to your private insurance plan, either directly by you or on your behalf.
• You are responsible for reporting use of the ELELYSO Co-pay Program to any private insurer, health plan, or other third party who pays for or reimburses any part of the prescription filled using the co-pay card, as may be required. You should not use the co-pay card if your insurer or health plan prohibits use of manufacturer co-pay cards.
• You must be 4 years of age or older to redeem the co-pay card.
• This co-pay card is not valid for Massachusetts residents whose prescriptions are covered in whole or in part by third party insurance.
• The ELELYSO Co-pay Program is not valid where prohibited by law.
• The benefit under the ELELYSO Co-pay Program is offered to, and intended for the sole benefit of, eligible patients and may not be transferred to or utilized for the benefit of third parties, including, without limitation, third party payers, pharmacy benefit managers, or the agents of either.
• Third party payers, pharmacy benefit managers, or the agents of either, are prohibited from assisting patients with enrolling in the ELELYSO Co-pay Program.
• The ELELYSO Co-pay Program cannot be combined with any other external savings, free trial or similar offer for the specified prescription (including any program offered by a third party payer or pharmacy benefit manager, or an agent of either, that adjusts patient cost-sharing obligations, through arrangements that may be referred to as “accumulator adjustment” or “co-pay maximizer” programs)
• Some health insurers or pharmacy benefit managers (or their agents) may have established accumulator adjustment or co-pay maximizer programs based on the availability of support under the ELELYSO Co-pay Program and/or exclude the financial assistance provided under the offer co-pay card program from counting towards patient deductibles or out-of-pocket cost limitations.
• Patients subject to an accumulator adjustment or co-pay maximizer program are not eligible for this offer. Since you may be unaware whether you are subject to an accumulator adjustment or co-pay maximizer program when you enroll in this offer, Pfizer may monitor program utilization data and reserves the right to discontinue, reduce, or otherwise modify this offer at any time without notice.
• Co-pay card will be accepted only at participating pharmacies.
• If your pharmacy does not participate, you may be able to submit a request for a rebate in connection with this offer.
• The ELELYSO Co-pay Program is not health insurance.
• Offer good only in the U.S. and Puerto Rico.
• The ELELYSO Co-pay Program is limited to 1 per person during this offering period and is not transferable.
• No other purchase is necessary.
• Data related to your redemption of the ELELYSO Co-pay Program may be collected, analyzed, and shared with Pfizer, for market research and other purposes related to assessing Pfizer’s programs. Data shared with Pfizer will be aggregated and de-identified; it will be combined with data related to other co-pay card redemptions and will not identify you.
• Pfizer reserves the right to rescind, revoke or amend this offer without notice.
• Offer expires 12/31/2026.

For questions regarding the offer, please call 1-855-353-5976, visit www.elelyso.com or write ELELYSO Co-pay Program, 430 Mountain Avenue, Suite 105, New Providence, NJ 07974.

ELREXFIO™ (elranatamab-bcmm)
Terms and Conditions:
By using the Pfizer Oncology Together™ Co-Pay Savings Program for Injectables for ELREXFIO, you acknowledge that you currently meet the eligibility criteria and will comply with the terms and conditions described below:

• Eligible patients with commercial prescription drug insurance coverage for ELREXFIO may pay as little as $0 per administered dose. Patient out-of-pocket expense will vary. The value of this offer is limited to annual benefit of $25,000. Once a patient reaches the annual maximum benefit patient is responsible for paying the remaining monthly out-of-pocket costs.
• Patients are not eligible for this offer if they are enrolled in a state or federally funded insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veteran Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico (formerly known as “La Reforma de Salud”).
• Patient must have private insurance. Offer is not valid for cash paying patients.
• This offer is not valid when the entire cost of your prescription drug is eligible to be reimbursed by your private insurance plan or other private health or pharmacy benefit programs.
• You must deduct the value of this offer from any reimbursement request submitted to your private insurance plan, either directly by you or on your behalf.
• You are responsible for reporting use of the Pfizer Oncology Together Co-Pay Savings Program for Injectables for ELREXFIO to any private insurer, health plan, or other third party who pays for or reimburses any part of the prescription filled using the co-pay card, as may be required. You should not use the co-pay card if your insurer or health plan prohibits use of manufacturer co-pay cards.
• Whether a co-pay expense is eligible for the Pfizer Oncology Together Injectables Co-Pay Program for ELREXFIO benefit will be determined at the time the benefit is paid. Co-pay expenses must be in connection with a separately paid claim for ELREXFIO administered in the outpatient setting.
• You must be 18 years of age or older to redeem the co-pay card.
• The Pfizer Oncology Together Co-Pay Savings Program for Injectables for ELREXFIO is not valid where prohibited by law.
• The benefit under the Pfizer Oncology Together Co-Pay Savings Program for Injectables for ELREXFIO is offered to, and intended for the sole benefit of, eligible patients and may not be transferred to or utilized for the benefit of third parties, including, without limitation, third party payers, pharmacy benefit managers, or the agents of either.
• Third party payers, pharmacy benefit managers, or the agents of either, are prohibited from assisting patients with enrolling in the Pfizer Oncology Together Co-Pay Savings Program for Injectables for ELREXFIO.
• The Pfizer Oncology Together Co-Pay Savings Program for Injectables for ELREXFIO cannot be combined with any other external savings, free trial or similar offer for the specified prescription (including any program offered by a third party payer or pharmacy benefit manager, or an agent of either, that adjusts patient cost-sharing obligations, through arrangements that may be referred to as “accumulator adjustment” or “co-pay maximizer” programs)
• Some health insurers or pharmacy benefit managers (or their agents) may have established accumulator adjustment or co-pay maximizer programs based on the availability of support under the Pfizer Oncology Together Co-Pay Savings Program for Injectables for ELREXFIO and/or exclude the financial assistance provided under the offer co-pay card program from counting towards patient deductibles or out-of-pocket cost limitations.
• Patients subject to an accumulator adjustment or co-pay maximizer program are not eligible for this offer. Since you may be unaware whether you are subject to an accumulator adjustment or co-pay maximizer program when you enroll in this offer, Pfizer may monitor program utilization data and reserves the right to discontinue, reduce, or otherwise modify this offer at any time without notice.
• Co-pay card will be accepted only at participating pharmacies.
• If your pharmacy does not participate, you may be able to submit a request for a rebate in connection with this offer.
• The Pfizer Oncology Together Co-Pay Savings Program for Injectables for ELREXFIO is not health insurance.
• Offer good only in the U.S. and Puerto Rico.
• The Pfizer Oncology Together Co-Pay Savings Program for Injectables for ELREXFIO is limited to 1 per person during this offering period and is not transferable.
• No other purchase is necessary.
• Data related to your redemption of the Pfizer Oncology Together Co-Pay Savings Program for Injectables for ELREXFIO may be collected, analyzed, and shared with Pfizer, for market research and other purposes related to assessing Pfizer’s programs. Data shared with Pfizer will be aggregated and de-identified; it will be combined with data related to other co-pay card redemptions and will not identify you.
• Pfizer reserves the right to rescind, revoke or amend this offer without notice.
• Offer expires 12/31/2026.
• For questions regarding the offer, please call 1-877-744-5675, visit https://www.pfizeroncologytogether.com/ or write Pfizer Oncology Together Co-Pay Savings Program for Injectables, 2730 S. Edmonds Lane, Suite 300, Lewisville, TX 75067.

INFLECTRA^® (infliximab-dyyb)
Terms and Conditions:
By using this Pfizer enCompass^® Co-Pay Assistance Program for INFLECTRA, you acknowledge that you currently meet the eligibility criteria and will comply with the terms and conditions described below:

• Eligible patients with commercial prescription drug insurance coverage for INFLECTRA may pay as little as $0 per administered dose. Patient out-of-pocket expense will vary. The value of this offer is limited to annual benefit of $3,000 to 12,000. Once a patient reaches the annual maximum benefit patient is responsible for paying the remaining monthly out-of-pocket costs.
• Patients are not eligible for this offer if they are enrolled in a state or federally funded insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veteran Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico (formerly known as “La Reforma de Salud”).
• Patient must have private insurance. Offer is not valid for cash paying patients.
• This offer is not valid when the entire cost of your prescription drug is eligible to be reimbursed by your private insurance plan or other private health or pharmacy benefit programs.
• You must deduct the value of this offer from any reimbursement request submitted to your private insurance plan, either directly by you or on your behalf.
• You are responsible for reporting use of the Pfizer enCompass^® Co-Pay Assistance Program for INFLECTRA to any private insurer, health plan, or other third party who pays for or reimburses any part of the prescription filled using the co-pay card, as may be required. You should not use the co-pay card if your insurer or health plan prohibits use of manufacturer co-pay cards.
• The Pfizer enCompass^® Co-Pay Assistance Program for INFLECTRA is not valid where prohibited by law.
• The benefit under Pfizer enCompass^® Co-Pay Assistance Program for INFLECTRA is offered to, and intended for the sole benefit of, eligible patients and may not be transferred to or utilized for the benefit of third parties, including, without limitation, third party payers, pharmacy benefit managers, or the agents of either.
• Third party payers, pharmacy benefit managers, or the agents of either, are prohibited from assisting patients with enrolling in the Pfizer enCompass^® Co-Pay Assistance Program for INFLECTRA.
• The Pfizer enCompass^® Co-Pay Assistance Program for INFLECTRA cannot be combined with any other external savings, free trial or similar offer for the specified prescription (including any program offered by a third party payer or pharmacy benefit manager, or an agent of either, that adjusts patient cost-sharing obligations, through arrangements that may be referred to as “accumulator adjustment” or “co-pay maximizer” programs)
• Some health insurers or pharmacy benefit managers (or their agents) may have established accumulator adjustment or co-pay maximizer programs based on the availability of support under the Pfizer enCompass^® Co-Pay Assistance Program for INFLECTRA and/or exclude the financial assistance provided under the offer co-pay card program from counting towards patient deductibles or out-of-pocket cost limitations.
• Patients subject to an accumulator adjustment or co-pay maximizer program are not eligible for this offer. Since you may be unaware whether you are subject to an accumulator adjustment or co-pay maximizer program when you enroll in this offer, Pfizer may monitor program utilization data and reserves the right to discontinue, reduce, or otherwise modify this offer at any time without notice.
• Co-pay card will be accepted only at participating pharmacies.
• If your pharmacy does not participate, you may be able to submit a request for a rebate in connection with this offer.
• The Pfizer enCompass^® Co-Pay Assistance Program for INFLECTRA is not health insurance.
• Offer good only in the U.S. and Puerto Rico.
• The Pfizer enCompass^® Co-Pay Assistance Program for INFLECTRA is limited to 1 per person during this offering period and is not transferable.
• No other purchase is necessary.
• Data related to your redemption of the Pfizer enCompass^® Co-Pay Assistance Program for INFLECTRA may be collected, analyzed, and shared with Pfizer, for market research and other purposes related to assessing Pfizer’s programs. Data shared with Pfizer will be aggregated and de-identified; it will be combined with data related to other co-pay card redemptions and will not identify you.
• Pfizer reserves the right to rescind, revoke or amend this offer without notice.
• Offer expires 12/31/2026.
• For questions regarding the offer, please call 1-844-722-6672, visit www.pfizerencompass.com or write Pfizer enCompass^® Co-Pay Assistance Program for INFLECTRA, 430 Mountain Avenue, Suite 105, New Providence, NJ 07974.

NIVESTYM^® (filgrastim-aafi)
Terms and Conditions:
By using the Pfizer Oncology Together™ Co-Pay Savings Program for Injectables for NIVESTYM, you acknowledge that you currently meet the eligibility criteria and will comply with the terms and conditions described below:

• Eligible patients with commercial prescription drug insurance coverage for NIVESTYM may pay as little as $0 per administered dose. Patient out-of-pocket expense will vary. The value of this offer is limited to annual benefit of $4,000 to $10,000. Once a patient reaches the annual maximum benefit patient is responsible for paying the remaining monthly out-of-pocket costs.
• Patients are not eligible for this offer if they are enrolled in a state or federally funded insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veteran Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico (formerly known as “La Reforma de Salud”).
• Patient must have private insurance. Offer is not valid for cash paying patients.
• This offer is not valid when the entire cost of your prescription drug is eligible to be reimbursed by your private insurance plan or other private health or pharmacy benefit programs.
• You must deduct the value of this offer from any reimbursement request submitted to your private insurance plan, either directly by you or on your behalf.
• You are responsible for reporting use of the Pfizer Oncology Together Co-Pay Savings Program for Injectables for NIVESTYM to any private insurer, health plan, or other third party who pays for or reimburses any part of the prescription filled using the co-pay card, as may be required. You should not use the co-pay card if your insurer or health plan prohibits use of manufacturer co-pay cards.
• Whether a co-pay expense is eligible for the Pfizer Oncology Together Injectables Co-Pay Program for NIVESTYM benefit will be determined at the time the benefit is paid. Co-pay expenses must be in connection with a separately paid claim for NIVESTYM administered in the outpatient setting.
• The Pfizer Oncology Together Co-Pay Savings Program for Injectables for NIVESTYM is not valid where prohibited by law.
• The benefit under the Pfizer Oncology Together Co-Pay Savings Program for Injectables for NIVESTYM is offered to, and intended for the sole benefit of, eligible patients and may not be transferred to or utilized for the benefit of third parties, including, without limitation, third party payers, pharmacy benefit managers, or the agents of either.
• Third party payers, pharmacy benefit managers, or the agents of either, are prohibited from assisting patients with enrolling in the Pfizer Oncology Together Co-Pay Savings Program for Injectables for NIVESTYM.
• The Pfizer Oncology Together Co-Pay Savings Program for Injectables for NIVESTYM cannot be combined with any other external savings, free trial or similar offer for the specified prescription (including any program offered by a third party payer or pharmacy benefit manager, or an agent of either, that adjusts patient cost-sharing obligations, through arrangements that may be referred to as “accumulator adjustment” or “co-pay maximizer” programs)
• Some health insurers or pharmacy benefit managers (or their agents) may have established accumulator adjustment or co-pay maximizer programs based on the availability of support under the Pfizer Oncology Together Co-Pay Savings Program for Injectables for NIVESTYM and/or exclude the financial assistance provided under the offer co-pay card program from counting towards patient deductibles or out-of-pocket cost limitations.
• Patients subject to an accumulator adjustment or co-pay maximizer program are not eligible for this offer. Since you may be unaware whether you are subject to an accumulator adjustment or co-pay maximizer program when you enroll in this offer, Pfizer may monitor program utilization data and reserves the right to discontinue, reduce, or otherwise modify this offer at any time without notice.
• Co-pay card will be accepted only at participating pharmacies.
• If your pharmacy does not participate, you may be able to submit a request for a rebate in connection with this offer.
• The Pfizer Oncology Together Co-Pay Savings Program for Injectables for NIVESTYM is not health insurance.
• Offer good only in the U.S. and Puerto Rico.
• The Pfizer Oncology Together Co-Pay Savings Program for Injectables for NIVESTYM is limited to 1 per person during this offering period and is not transferable.
• No other purchase is necessary.
• Data related to your redemption of the Pfizer Oncology Together Co-Pay Savings Program for Injectables for NIVESTYM may be collected, analyzed, and shared with Pfizer, for market research and other purposes related to assessing Pfizer’s programs. Data shared with Pfizer will be aggregated and de-identified; it will be combined with data related to other co-pay card redemptions and will not identify you.
• Pfizer reserves the right to rescind, revoke or amend this offer without notice.
• Offer expires 12/31/2026.
• For questions regarding the offer, please call 1-877-744-5675, visit https://www.pfizeroncologytogether.com/ or write Pfizer Oncology Together Co-Pay Savings Program for Injectables, 2730 S. Edmonds Lane, Suite 300, Lewisville, TX 75067.

NYVEPRIA^® (pegfilgrastim-apgf)
Terms and Conditions:
By using the Pfizer Oncology Together™ Co-Pay Savings Program for Injectables for NYVEPRIA, you acknowledge that you currently meet the eligibility criteria and will comply with the terms and conditions described below:

• Eligible patients with commercial prescription drug insurance coverage for NYVEPRIA may pay as little as $0 per administered dose. Patient out-of-pocket expense will vary. The value of this offer is limited to annual benefit of $4,000 to $10,000. Once a patient reaches the annual maximum benefit patient is responsible for paying the remaining monthly out-of-pocket costs.
• Patients are not eligible for this offer if they are enrolled in a state or federally funded insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veteran Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico (formerly known as “La Reforma de Salud”).
• Patient must have private insurance. Offer is not valid for cash paying patients.
• This offer is not valid when the entire cost of your prescription drug is eligible to be reimbursed by your private insurance plan or other private health or pharmacy benefit programs.
• You must deduct the value of this offer from any reimbursement request submitted to your private insurance plan, either directly by you or on your behalf.
• You are responsible for reporting use of the Pfizer Oncology Together Co-Pay Savings Program for Injectables for NYVEPRIA to any private insurer, health plan, or other third party who pays for or reimburses any part of the prescription filled using the co-pay card, as may be required. You should not use the co-pay card if your insurer or health plan prohibits use of manufacturer co-pay cards.
• Whether a co-pay expense is eligible for the Pfizer Oncology Together Injectables Co-Pay Program for NYVEPRIA benefit will be determined at the time the benefit is paid. Co-pay expenses must be in connection with a separately paid claim for NYVEPRIA administered in the outpatient setting.
• The Pfizer Oncology Together Co-Pay Savings Program for Injectables for NYVEPRIA is not valid where prohibited by law.
• The benefit under the Pfizer Oncology Together Co-Pay Savings Program for Injectables for NYVEPRIA is offered to, and intended for the sole benefit of, eligible patients and may not be transferred to or utilized for the benefit of third parties, including, without limitation, third party payers, pharmacy benefit managers, or the agents of either.
• Third party payers, pharmacy benefit managers, or the agents of either, are prohibited from assisting patients with enrolling in the Pfizer Oncology Together Co-Pay Savings Program for Injectables for NYVEPRIA.
• The Pfizer Oncology Together Co-Pay Savings Program for Injectables for NYVEPRIA cannot be combined with any other external savings, free trial or similar offer for the specified prescription (including any program offered by a third party payer or pharmacy benefit manager, or an agent of either, that adjusts patient cost-sharing obligations, through arrangements that may be referred to as “accumulator adjustment” or “co-pay maximizer” programs)
• Some health insurers or pharmacy benefit managers (or their agents) may have established accumulator adjustment or co-pay maximizer programs based on the availability of support under the Pfizer Oncology Together Co-Pay Savings Program for Injectables for NYVEPRIA and/or exclude the financial assistance provided under the offer co-pay card program from counting towards patient deductibles or out-of-pocket cost limitations.
• Patients subject to an accumulator adjustment or co-pay maximizer program are not eligible for this offer. Since you may be unaware whether you are subject to an accumulator adjustment or co-pay maximizer program when you enroll in this offer, Pfizer may monitor program utilization data and reserves the right to discontinue, reduce, or otherwise modify this offer at any time without notice.
• Co-pay card will be accepted only at participating pharmacies.
• If your pharmacy does not participate, you may be able to submit a request for a rebate in connection with this offer.
• The Pfizer Oncology Together Co-Pay Savings Program for Injectables for NYVEPRIA is not health insurance.
• Offer good only in the U.S. and Puerto Rico.
• The Pfizer Oncology Together Co-Pay Savings Program for Injectables for NYVEPRIA is limited to 1 per person during this offering period and is not transferable.
• No other purchase is necessary.
• Data related to your redemption of the Pfizer Oncology Together Co-Pay Savings Program for Injectables for NYVEPRIA may be collected, analyzed, and shared with Pfizer, for market research and other purposes related to assessing Pfizer’s programs. Data shared with Pfizer will be aggregated and de-identified; it will be combined with data related to other co-pay card redemptions and will not identify you.
• Pfizer reserves the right to rescind, revoke or amend this offer without notice.
• Offer expires 12/31/2026.
• For questions regarding the offer, please call 1-877-744-5675, visit https://www.pfizeroncologytogether.com/ or write Pfizer Oncology Together Co-Pay Savings Program for Injectables, 2730 S. Edmonds Lane, Suite 300, Lewisville, TX 75067.

RUXIENCE^® (rituximab-pvvr)
Terms and Conditions:
By using the Pfizer Oncology Together™ Co-Pay Savings Program for Injectables for RUXIENCE and the Pfizer enCompass Co-Pay^® Assistance Program for RUXIENCE, you acknowledge that you currently meet the eligibility criteria and will comply with the terms and conditions described below:

• Eligible patients with commercial prescription drug insurance coverage for RUXIENCE may pay as little as $0 per administered dose. Patient out-of-pocket expense will vary. The value of this offer is limited to annual benefit of $25,000. Once a patient reaches the annual maximum benefit patient is responsible for paying the remaining monthly out-of-pocket costs.
• Patients are not eligible for this offer if they are enrolled in a state or federally funded insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veteran Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico (formerly known as “La Reforma de Salud”).
• Patients prescribed RUXIENCE for pemphigus vulgaris are not eligible for this co-pay savings program.
• Patient must have private insurance. Offer is not valid for cash paying patients.
• This offer is not valid when the entire cost of your prescription drug is eligible to be reimbursed by your private insurance plan or other private health or pharmacy benefit programs.
• You must deduct the value of this offer from any reimbursement request submitted to your private insurance plan, either directly by you or on your behalf.
• You are responsible for reporting use of the Pfizer Oncology Together Co-Pay Savings Program for Injectables for RUXIENCE and the Pfizer enCompass Co-Pay Assistance Program for RUXIENCE to any private insurer, health plan, or other third party who pays for or reimburses any part of the prescription filled using the co-pay card, as may be required. You should not use the co-pay card if your insurer or health plan prohibits use of manufacturer co-pay cards.
• Whether a co-pay expense is eligible for the Pfizer Oncology Together Co-Pay Savings Program for Injectables for RUXIENCE and the Pfizer enCompass Co-Pay Assistance Program for RUXIENCE benefit will be determined at the time the benefit is paid. Co-pay expenses must be in connection with a separately paid claim for RUXIENCE administered in the outpatient setting.
• You must be 18 years of age or older to redeem the co-pay card.
• The Pfizer Oncology Together Co-Pay Savings Program for Injectables for RUXIENCE and the Pfizer enCompass Co-Pay Assistance Program for RUXIENCE is not valid where prohibited by law.
• The benefit under the Pfizer Oncology Together Co-Pay Savings Program for Injectables for RUXIENCE and the Pfizer enCompass Co-Pay Assistance Program for RUXIENCE is offered to, and intended for the sole benefit of, eligible patients and may not be transferred to or utilized for the benefit of third parties, including, without limitation, third party payers, pharmacy benefit managers, or the agents of either.
• Third party payers, pharmacy benefit managers, or the agents of either, are prohibited from assisting patients with enrolling in the Pfizer Oncology Together Co-Pay Savings Program for Injectables for RUXIENCE.
• The Pfizer Oncology Together Co-Pay Savings Program for Injectables for RUXIENCE and the Pfizer enCompass Co-Pay Assistance Program for RUXIENCE cannot be combined with any other external savings, free trial or similar offer for the specified prescription (including any program offered by a third party payer or pharmacy benefit manager, or an agent of either, that adjusts patient cost-sharing obligations, through arrangements that may be referred to as “accumulator adjustment” or “co-pay maximizer” programs)
• Some health insurers or pharmacy benefit managers (or their agents) may have established accumulator adjustment or co-pay maximizer programs based on the availability of support under the Pfizer Oncology Together Co-Pay Savings Program for Injectables for RUXIENCE and the Pfizer enCompass Co-Pay Assistance Program for RUXIENCE and/or exclude the financial assistance provided under the offer co-pay card program from counting towards patient deductibles or out-of-pocket cost limitations.
• Patients subject to an accumulator adjustment or co-pay maximizer program are not eligible for this offer. Since you may be unaware whether you are subject to an accumulator adjustment or co-pay maximizer program when you enroll in this offer, Pfizer may monitor program utilization data and reserves the right to discontinue, reduce, or otherwise modify this offer at any time without notice.
• Co-pay card will be accepted only at participating pharmacies.
• If your pharmacy does not participate, you may be able to submit a request for a rebate in connection with this offer.
• The Pfizer Oncology Together Co-Pay Savings Program for Injectables for RUXIENCE and the Pfizer enCompass Co-Pay Assistance Program for RUXIENCE is not health insurance.
• Offer good only in the U.S. and Puerto Rico.
• The Pfizer Oncology Together Co-Pay Savings Program for Injectables for RUXIENCE and the Pfizer enCompass Co-Pay Assistance Program for RUXIENCE is limited to 1 per person during this offering period and is not transferable.
• No other purchase is necessary.
• Data related to your redemption of the Pfizer Oncology Together Co-Pay Savings Program for Injectables for RUXIENCE and the Pfizer enCompass Co-Pay Assistance Program for RUXIENCE may be collected, analyzed, and shared with Pfizer, for market research and other purposes related to assessing Pfizer’s programs. Data shared with Pfizer will be aggregated and de-identified; it will be combined with data related to other co-pay card redemptions and will not identify you.
• Pfizer reserves the right to rescind, revoke or amend this offer without notice.
• Offer expires 12/31/2026.
• For questions regarding the offer for oncology indications, please call 1-877-744-5675, visit https://www.pfizeroncologytogether.com/ or write Pfizer Oncology Together Co-Pay Savings Program for Injectables for RUXIENCE, 2730 S. Edmonds Lane, Suite 300, Lewisville, TX 75067. For questions regarding the offer for non-oncology indications, please call 1-844-722-6672, visit https://www.pfizerencompass.com/ or write Pfizer enCompass Co-Pay Assistance Program for RUXIENCE, 430 Mountain Avenue, Suite 105, New Providence, NJ 07974.

TIVDAK^® (tisotumab vedotin-tftv)
Terms and Conditions:
By using the Pfizer Oncology Together™ Co-Pay Savings Program for Injectables for TIVDAK, you acknowledge that you currently meet the eligibility criteria and will comply with the terms and conditions described below:

• Eligible patients with commercial prescription drug insurance coverage for TIVDAK may pay as little as $0 per administered dose. Patient out-of-pocket expense will vary. The value of this offer is limited to annual benefit of $25,000. Once a patient reaches the annual maximum benefit patient is responsible for paying the remaining monthly out-of-pocket costs.
• Patients are not eligible for this offer if they are enrolled in a state or federally funded insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veteran Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico (formerly known as “La Reforma de Salud”).
• Patient must have private insurance. Offer is not valid for cash paying patients.
• This offer is not valid when the entire cost of your prescription drug is eligible to be reimbursed by your private insurance plan or other private health or pharmacy benefit programs.
• You must deduct the value of this offer from any reimbursement request submitted to your private insurance plan, either directly by you or on your behalf.
• You are responsible for reporting use of the Pfizer Oncology Together Co-Pay Savings Program for Injectables for TIVDAK to any private insurer, health plan, or other third party who pays for or reimburses any part of the prescription filled using the co-pay card, as may be required. You should not use the co-pay card if your insurer or health plan prohibits use of manufacturer co-pay cards.
• You must be 18 years of age or older to redeem the co-pay card.
• The Pfizer Oncology Together Co-Pay Savings Program for Injectables for TIVDAK is not valid where prohibited by law.
• The benefit under the Pfizer Oncology Together Co-Pay Savings Program for Injectables for TIVDAK is offered to, and intended for the sole benefit of, eligible patients and may not be transferred to or utilized for the benefit of third parties, including, without limitation, third party payers, pharmacy benefit managers, or the agents of either.
• Third party payers, pharmacy benefit managers, or the agents of either, are prohibited from assisting patients with enrolling in the Pfizer Oncology Together Co-Pay Savings Program for Injectables for TIVDAK.
• The Pfizer Oncology Together Co-Pay Savings Program for Injectables for TIVDAK cannot be combined with any other external savings, free trial or similar offer for the specified prescription (including any program offered by a third party payer or pharmacy benefit manager, or an agent of either, that adjusts patient cost-sharing obligations, through arrangements that may be referred to as “accumulator adjustment” or “co-pay maximizer” programs)
• Some health insurers or pharmacy benefit managers (or their agents) may have established accumulator adjustment or co-pay maximizer programs based on the availability of support under the Pfizer Oncology Together Co-Pay Savings Program for Injectables for TIVDAK and/or exclude the financial assistance provided under the offer co-pay card program from counting towards patient deductibles or out-of-pocket cost limitations.
• Patients subject to an accumulator adjustment or co-pay maximizer program are not eligible for this offer. Since you may be unaware whether you are subject to an accumulator adjustment or co-pay maximizer program when you enroll in this offer, Pfizer may monitor program utilization data and reserves the right to discontinue, reduce, or otherwise modify this offer at any time without notice.
• Co-pay card will be accepted only at participating pharmacies.
• If your pharmacy does not participate, you may be able to submit a request for a rebate in connection with this offer.
• The Pfizer Oncology Together Co-Pay Savings Program for Injectables for TIVDAK is not health insurance.
• Offer good only in the U.S. and Puerto Rico.
• The Pfizer Oncology Together Co-Pay Savings Program for Injectables for TIVDAK is limited to 1 per person during this offering period and is not transferable.
• No other purchase is necessary.
• Data related to your redemption of the Pfizer Oncology Together Co-Pay Savings Program for Injectables for TIVDAK may be collected, analyzed, and shared with Pfizer, for market research and other purposes related to assessing Pfizer’s programs. Data shared with Pfizer will be aggregated and de-identified; it will be combined with data related to other co-pay card redemptions and will not identify you.
• Pfizer reserves the right to rescind, revoke or amend this offer without notice.
• Offer expires 12/31/2026.
• For questions regarding the offer, please call 1-877-744-5675, visit https://www.pfizeroncologytogether.com/ or write Pfizer Oncology Together Co-Pay Savings Program for Injectables, 2730 S. Edmonds Lane, Suite 300, Lewisville, TX 75067.

TRAZIMERA^® (trastuzumab-qyyp)
Terms and Conditions:
By using the Pfizer Oncology Together™ Co-Pay Savings Program for Injectables for TRAZIMERA, you acknowledge that you currently meet the eligibility criteria and will comply with the terms and conditions described below:

• Eligible patients with commercial prescription drug insurance coverage for TRAZIMERA may pay as little as $0 per administered dose. Patient out-of-pocket expense will vary. The value of this offer is limited to annual benefit of $25,000. Once a patient reaches the annual maximum benefit patient is responsible for paying the remaining monthly out-of-pocket costs.
• Patients are not eligible for this offer if they are enrolled in a state or federally funded insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veteran Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico (formerly known as “La Reforma de Salud”).
• Patient must have private insurance. Offer is not valid for cash paying patients.
• This offer is not valid when the entire cost of your prescription drug is eligible to be reimbursed by your private insurance plan or other private health or pharmacy benefit programs.
• You must deduct the value of this offer from any reimbursement request submitted to your private insurance plan, either directly by you or on your behalf.
• You are responsible for reporting use of the Pfizer Oncology Together Co-Pay Savings Program for Injectables for TRAZIMERA to any private insurer, health plan, or other third party who pays for or reimburses any part of the prescription filled using the co-pay card, as may be required. You should not use the co-pay card if your insurer or health plan prohibits use of manufacturer co-pay cards.
• Whether a co-pay expense is eligible for the Injectables Co-Pay Program for TRAZIMERA benefit will be determined at the time the benefit is paid. Co-pay expenses must be in connection with a separately paid claim for TRAZIMERA administered in the outpatient setting.
• You must be 18 years of age or older to redeem the co-pay card.
• The Pfizer Oncology Together Co-Pay Savings Program for Injectables for TRAZIMERA is not valid where prohibited by law.
• The benefit under the Pfizer Oncology Together Co-Pay Savings Program for Injectables for TRAZIMERA is offered to, and intended for the sole benefit of, eligible patients and may not be transferred to or utilized for the benefit of third parties, including, without limitation, third party payers, pharmacy benefit managers, or the agents of either.
• Third party payers, pharmacy benefit managers, or the agents of either, are prohibited from assisting patients with enrolling in the Pfizer Oncology Together Co-Pay Savings Program for Injectables for TRAZIMERA.
• The Pfizer Oncology Together Co-Pay Savings Program for Injectables for TRAZIMERA cannot be combined with any other external savings, free trial or similar offer for the specified prescription (including any program offered by a third party payer or pharmacy benefit manager, or an agent of either, that adjusts patient cost-sharing obligations, through arrangements that may be referred to as “accumulator adjustment” or “co-pay maximizer” programs)
• Some health insurers or pharmacy benefit managers (or their agents) may have established accumulator adjustment or co-pay maximizer programs based on the availability of support under the Pfizer Oncology Together Co-Pay Savings Program for Injectables for TRAZIMERA and/or exclude the financial assistance provided under the offer co-pay card program from counting towards patient deductibles or out-of-pocket cost limitations.
• Patients subject to an accumulator adjustment or co-pay maximizer program are not eligible for this offer. Since you may be unaware whether you are subject to an accumulator adjustment or co-pay maximizer program when you enroll in this offer, Pfizer may monitor program utilization data and reserves the right to discontinue, reduce, or otherwise modify this offer at any time without notice.
• Co-pay card will be accepted only at participating pharmacies.
• If your pharmacy does not participate, you may be able to submit a request for a rebate in connection with this offer.
• The Pfizer Oncology Together Co-Pay Savings Program for Injectables for TRAZIMERA is not health insurance.
• Offer good only in the U.S. and Puerto Rico.
• The Pfizer Oncology Together Co-Pay Savings Program for Injectables for TRAZIMERA is limited to 1 per person during this offering period and is not transferable.
• No other purchase is necessary.
• Data related to your redemption of the Pfizer Oncology Together Co-Pay Savings Program for Injectables for TRAZIMERA may be collected, analyzed, and shared with Pfizer, for market research and other purposes related to assessing Pfizer’s programs. Data shared with Pfizer will be aggregated and de-identified; it will be combined with data related to other co-pay card redemptions and will not identify you.
• Pfizer reserves the right to rescind, revoke or amend this offer without notice.
• Offer expires 12/31/2026.
• For questions regarding the offer, please call 1-877-744-5675, visit https://www.pfizeroncologytogether.com/ or write Pfizer Oncology Together Co-Pay Savings Program for Injectables, 2730 S. Edmonds Lane, Suite 300, Lewisville, TX 75067.

ZIRABEV^® (bevacizumab-bvzr)
Terms and Conditions:
By using the Pfizer Oncology Together™ Co-Pay Savings Program for Injectables for ZIRABEV, you acknowledge that you currently meet the eligibility criteria and will comply with the terms and conditions described below:

• Eligible patients with commercial prescription drug insurance coverage for ZIRABEV may pay as little as $0 per administered dose. Patient out-of-pocket expense will vary. The value of this offer is limited to annual benefit of $25,000. Once a patient reaches the annual maximum benefit patient is responsible for paying the remaining monthly out-of-pocket costs.
• Patients are not eligible for this offer if they are enrolled in a state or federally funded insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veteran Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico (formerly known as “La Reforma de Salud”).
• Patient must have private insurance. Offer is not valid for cash paying patients.
• This offer is not valid when the entire cost of your prescription drug is eligible to be reimbursed by your private insurance plan or other private health or pharmacy benefit programs.
• Patients prescribed ZIRABEV for hepatocellular carcinoma are not eligible for this co-pay savings program.
• You must deduct the value of this offer from any reimbursement request submitted to your private insurance plan, either directly by you or on your behalf.
• You are responsible for reporting use of the Pfizer Oncology Together Co-Pay Savings Program for Injectables for ZIRABEV to any private insurer, health plan, or other third party who pays for or reimburses any part of the prescription filled using the co-pay card, as may be required. You should not use the co-pay card if your insurer or health plan prohibits use of manufacturer co-pay cards.
• Whether a co-pay expense is eligible for the Injectables Co-Pay Program for ZIRABEV benefit will be determined at the time the benefit is paid. Co-pay expenses must be in connection with a separately paid claim for ZIRABEV administered in the outpatient setting.
• You must be 18 years of age or older to redeem the co-pay card.
• The Pfizer Oncology Together Co-Pay Savings Program for Injectables for ZIRABEV is not valid where prohibited by law.
• The benefit under the Pfizer Oncology Together Co-Pay Savings Program for Injectables for ZIRABEV is offered to, and intended for the sole benefit of, eligible patients and may not be transferred to or utilized for the benefit of third parties, including, without limitation, third party payers, pharmacy benefit managers, or the agents of either.
• Third party payers, pharmacy benefit managers, or the agents of either, are prohibited from assisting patients with enrolling in the Pfizer Oncology Together Co-Pay Savings Program for Injectables for ZIRABEV.
• The Pfizer Oncology Together Co-Pay Savings Program for Injectables for ZIRABEV cannot be combined with any other external savings, free trial or similar offer for the specified prescription (including any program offered by a third party payer or pharmacy benefit manager, or an agent of either, that adjusts patient cost-sharing obligations, through arrangements that may be referred to as “accumulator adjustment” or “co-pay maximizer” programs)
• Some health insurers or pharmacy benefit managers (or their agents) may have established accumulator adjustment or co-pay maximizer programs based on the availability of support under the Pfizer Oncology Together Co-Pay Savings Program for Injectables for ZIRABEV and/or exclude the financial assistance provided under the offer co-pay card program from counting towards patient deductibles or out-of-pocket cost limitations.
• Patients subject to an accumulator adjustment or co-pay maximizer program are not eligible for this offer. Since you may be unaware whether you are subject to an accumulator adjustment or co-pay maximizer program when you enroll in this offer, Pfizer may monitor program utilization data and reserves the right to discontinue, reduce, or otherwise modify this offer at any time without notice.
• Co-pay card will be accepted only at participating pharmacies.
• If your pharmacy does not participate, you may be able to submit a request for a rebate in connection with this offer.
• The Pfizer Oncology Together Co-Pay Savings Program for Injectables for ZIRABEV is not health insurance.
• Offer good only in the U.S. and Puerto Rico.
• The Pfizer Oncology Together Co-Pay Savings Program for Injectables for ZIRABEV is limited to 1 per person during this offering period and is not transferable.
• No other purchase is necessary.
• Data related to your redemption of the Pfizer Oncology Together Co-Pay Savings Program for Injectables for ZIRABEV may be collected, analyzed, and shared with Pfizer, for market research and other purposes related to assessing Pfizer’s programs. Data shared with Pfizer will be aggregated and de-identified; it will be combined with data related to other co-pay card redemptions and will not identify you.
• Pfizer reserves the right to rescind, revoke or amend this offer without notice.
• Offer expires 12/31/2026.
• For questions regarding the offer, please call 1-877-744-5675, visit https://www.pfizeroncologytogether.com/ or write Pfizer Oncology Together Co-Pay Savings Program for Injectables, 2730 S. Edmonds Lane, Suite 300, Lewisville, TX 75067.